(1S,2R,18R,19R,22S,25R,28R,40S)-2-[(2R,4S,5R,6S)-4-Amino-5-Hydroxy-4,6-Dimethyloxan-2-Yl]Oxy-22-(2-Amino-2-Oxoethyl)-5,15-Dichloro-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5R,6S)-4-[[4-(4-Chlorophenyl)Phenyl]Methylamino]-5-Hydroxy-4,6-Dimethyloxan-2-Yl]Oxy-4,5-Dihydroxy-6-(Hydroxymethyl)Oxan-2-Yl]Oxy-18,32,35,37-Tetrahydroxy-19-[[(2R)-4-Methyl-2-(Methylamino)Pentanoyl]Amino]-20,23,26,42,44-Pentaoxo-7,13-Dioxa-21,24,27,41,43-Pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]Pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34(39),35,37,46,49-Pentadecaene-40-Carboxylic Acid;Phosphoric Acid,碳酸氢钠,置于crude Product,乙腈,三氟乙酸体系中,用 1,4-二氧六环,水 用作溶剂,化学反应 48.0H,以to Give 12 (102 Mg,24%) As A White Solid的收率获得奥利万星
参考文献:Glycopeptide And Lipoglycopeptide Antibiotics With Improved Solubility
标题:Glycopeptide And Lipoglycopeptide Antibiotics With Improved Solubility
摘要:本发明涉及与母体糖肽或脂肽糖肽抗生素具有不同离子化状态的糖肽衍生物和脂肽糖肽衍生物,并具有在生理条件下再生为母体糖肽或脂肽糖肽抗生素的能力.这些化合物可用作预防和/或治疗细菌感染的抗生素.